Allspring Global Investments
PTGX icon

Allspring Global Investments’s Protagonist Therapeutics PTGX Stock Holding History

Allspring Global Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Buy
29,916
+25,931
+651% +$2.3M 0.01% 964
2025
Q4 		$347K Buy
+3,985
New +$326K ﹤0.01% 1476
2025
Q1 		– Sell
-5,975
Closed -$231K – 1802
2024
Q4 		$231K Sell
5,975
-97,867
-94% -$4.27M ﹤0.01% 1647
2024
Q3 		$4.67M Buy
103,842
+103,414
+24,162% +$4.18M 0.01% 962
2024
Q2 		$14.8K Sell
428
-1,542
-78% -$45.2K ﹤0.01% 2164
2024
Q1 		$57K Sell
1,970
-563
-22% -$15.3K ﹤0.01% 1929
2023
Q4 		$58.1K Sell
2,533
-5,973
-70% -$105K ﹤0.01% 1868
2023
Q3 		$142K Sell
8,506
-167,023
-95% -$3.24M ﹤0.01% 1865
2023
Q2 		$4.85M Sell
175,529
-48,135
-22% -$1.2M 0.01% 1011
2023
Q1 		$5.14M Buy
223,664
+217,761
+3,689% +$3.66M 0.01% 985
2022
Q4 		$64.4K Sell
5,903
-5,784
-49% -$48.8K ﹤0.01% 2239
2022
Q3 		$98K Buy
11,687
+1,375
+13% +$13K ﹤0.01% 2093
2022
Q2 		$81K Sell
10,312
-16,994
-62% -$205K ﹤0.01% 2123
2022
Q1 		$646K Buy
27,306
+1,935
+8% +$54.5K ﹤0.01% 2111
2021
Q4 		$867K Buy
+25,371
New +$802K ﹤0.01% 2026

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Allspring Global Investments's PTGX Position: Q1 2026 in Review

Allspring Global Investments increased its Protagonist Therapeutics (PTGX) stake by 651% in Q1 2026, buying an estimated $2.3M and bringing the position to 29,916 shares worth $3.1M. The position accounts for 0.01% of the portfolio, ranked #964.

Allspring Global Investments first reported a position in PTGX in Q4 2021 and has held it in 15 quarters since. The position peaked at $5.14M in Q1 2023. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Allspring Global Investments held 29,916 shares of Protagonist Therapeutics worth $3.1M as of Q1 2026.
  • Allspring Global Investments bought 25,931 Protagonist Therapeutics shares in Q1 2026, an estimated $2.3M.
  • Protagonist Therapeutics made up 0.01% of Allspring Global Investments's portfolio in Q1 2026, its #964 holding.
  • Allspring Global Investments first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Allspring Global Investments's Protagonist Therapeutics position peaked at $5.14M in Q1 2023.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Allspring Global Investments's 13F filing for Q1 2026, filed 5 May 2026.